Loading...
Market
When will AbbVie announce successful Phase 1 results for ALIA-1758?
2
Resolution / Starting Odds
Q4 2024 • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
AbbVie's official press releases or clinical trial registries
Story
AbbVie to Acquire J&J-Backed Aliada Therapeutics for $1.4 Billion in Alzheimer's Focus
Oct 28, 2024, 01:52 PM
AbbVie Inc. announced on Monday that it will acquire Aliada Therapeutics, a privately held therapy developer, for $1.4 billion in cash. The acquisition is aimed at strengthening AbbVie's focus on Alzheimer's disease and its neuroscience pipeline. Aliada Therapeutics, a J&J-backed company, is known for its lead compound ALIA-1758 and its novel blood-brain barrier technology, which are expected to enhance AbbVie's capabilities in developing treatments for neurodegenerative diseases. This deal, involving a Phase 1 biotech, marks AbbVie's third acquisition of the year and underscores its commitment to expanding its research and development in the central nervous system (CNS) domain.
View original story
Similar markets
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Initiated before January 1, 2025 • 25%
Initiated between January 1, 2025 and March 31, 2025 • 25%
Initiated between April 1, 2025 and June 30, 2025 • 25%
Not initiated by June 30, 2025 • 25%